Inhibition of cell-mediated immunity in patients with brain tumors.
The immunocompetence of patients with glioblastomas, but not patients with astrocytomas, is altered. In vitro testing demonstrates an inhibitory factor in the serum of patients with glioblastomas which impairs lymphocytic responsiveness. The degree of this impairment appears important in relation to the clinical course.